AI-generated summary
The authors randomized postmenopausal women with vulvovaginal atrophy to vaginal CO2 laser therapy alone or with oral L. crispatus M247 for 90 days. Both groups improved in vaginal pH and symptom scores, and the combined group showed lower symptom scores at Day 90 in selected domains, with wide confidence intervals and nominal p-values. Microbiota shifts toward L. crispatus were seen only in the combined group, in a subset of participants.
- Who or what was studied
- Postmenopausal women with vulvovaginal atrophy
- Limits stated in the abstract
- Confidence intervals were wide for several clinical estimates, p-values were not adjusted for multiplicity, and microbiota analysis was done in only a subset of participants.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Visual analogue scale. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.